196 related articles for article (PubMed ID: 26462516)
41. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
Jenkins D
Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
[TBL] [Abstract][Full Text] [Related]
42. Genital human papillomavirus infection.
Dunne EF; Markowitz LE
Clin Infect Dis; 2006 Sep; 43(5):624-9. PubMed ID: 16886157
[TBL] [Abstract][Full Text] [Related]
43. HPV infection and cervical disease: a review.
Carter JR; Ding Z; Rose BR
Aust N Z J Obstet Gynaecol; 2011 Apr; 51(2):103-8. PubMed ID: 21466509
[TBL] [Abstract][Full Text] [Related]
44. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine.
Goldie SJ; Grima D; Kohli M; Wright TC; Weinstein M; Franco E
Int J Cancer; 2003 Oct; 106(6):896-904. PubMed ID: 12918067
[TBL] [Abstract][Full Text] [Related]
45. Cervical cancer: A comprehensive approach towards extermination.
Bava SV; Thulasidasan AK; Sreekanth CN; Anto RJ
Ann Med; 2016; 48(3):149-61. PubMed ID: 26911282
[TBL] [Abstract][Full Text] [Related]
46. Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination.
Stern PL
J Clin Virol; 2005 Mar; 32 Suppl 1():S72-81. PubMed ID: 15753015
[TBL] [Abstract][Full Text] [Related]
47. The Double-Edged Sword-How Human Papillomaviruses Interact With Immunity in Head and Neck Cancer.
Wang HF; Wang SS; Tang YJ; Chen Y; Zheng M; Tang YL; Liang XH
Front Immunol; 2019; 10():653. PubMed ID: 31001266
[TBL] [Abstract][Full Text] [Related]
48. [Advances in Understanding Carcinogenetic Mechanisms of the Human Papillomavirus and Vaccines Based on Virus-like Particles].
Zhao Z; Wang L; Ma B
Bing Du Xue Bao; 2015 Mar; 31(2):180-6. PubMed ID: 26164945
[TBL] [Abstract][Full Text] [Related]
49. [HPV immunization for the prevention of cervical cancer].
Mougin C; Bourgault-Villada I; Coursaget P
Presse Med; 2009 Dec; 38(12):1750-68. PubMed ID: 19765945
[TBL] [Abstract][Full Text] [Related]
50. Human papillomaviruses and cervical cancer.
DiMaio D; Liao JB
Adv Virus Res; 2006; 66():125-59. PubMed ID: 16877060
[TBL] [Abstract][Full Text] [Related]
51. Human papillomavirus vaccines for the prevention and treatment of cervical cancer.
Tomson TT; Roden RB; Wu TC
Curr Opin Investig Drugs; 2004 Dec; 5(12):1247-61. PubMed ID: 15648945
[TBL] [Abstract][Full Text] [Related]
52. HPV post-infection microenvironment and cervical cancer.
Yuan Y; Cai X; Shen F; Ma F
Cancer Lett; 2021 Jan; 497():243-254. PubMed ID: 33122098
[TBL] [Abstract][Full Text] [Related]
53. Association between toll-like receptor expression and human papillomavirus type 16 persistence.
Daud II; Scott ME; Ma Y; Shiboski S; Farhat S; Moscicki AB
Int J Cancer; 2011 Feb; 128(4):879-86. PubMed ID: 20473890
[TBL] [Abstract][Full Text] [Related]
54. Pathogenic role of exosomes and microRNAs in HPV-mediated inflammation and cervical cancer: A review.
Sadri Nahand J; Moghoofei M; Salmaninejad A; Bahmanpour Z; Karimzadeh M; Nasiri M; Mirzaei HR; Pourhanifeh MH; Bokharaei-Salim F; Mirzaei H; Hamblin MR
Int J Cancer; 2020 Jan; 146(2):305-320. PubMed ID: 31566705
[TBL] [Abstract][Full Text] [Related]
55. HPV infection: immunological aspects and their utility in future therapy.
Deligeoroglou E; Giannouli A; Athanasopoulos N; Karountzos V; Vatopoulou A; Dimopoulos K; Creatsas G
Infect Dis Obstet Gynecol; 2013; 2013():540850. PubMed ID: 24023507
[TBL] [Abstract][Full Text] [Related]
56. Is there a role played by HLA-E, if any, in HPV immune evasion?
Franciosi JR; Gelmini GF; Roxo VS; de Carvalho NS; Bicalho MDG
Scand J Immunol; 2020 Mar; 91(3):e12850. PubMed ID: 31733115
[TBL] [Abstract][Full Text] [Related]
57. The Role of HLA-G in Human Papillomavirus Infections and Cervical Carcinogenesis.
Xu HH; Yan WH; Lin A
Front Immunol; 2020; 11():1349. PubMed ID: 32670296
[TBL] [Abstract][Full Text] [Related]
58. The HPV viral regulatory mechanism of TLRs and the related treatments for HPV-associated cancers.
Qi SY; Yang MM; Li CY; Yu K; Deng SL
Front Immunol; 2024; 15():1407649. PubMed ID: 38812510
[TBL] [Abstract][Full Text] [Related]
59. A Human Papillomavirus-Independent Cervical Cancer Animal Model Reveals Unconventional Mechanisms of Cervical Carcinogenesis.
He C; Lv X; Huang C; Angeletti PC; Hua G; Dong J; Zhou J; Wang Z; Ma B; Chen X; Lambert PF; Rueda BR; Davis JS; Wang C
Cell Rep; 2019 Mar; 26(10):2636-2650.e5. PubMed ID: 30840887
[TBL] [Abstract][Full Text] [Related]
60. Gut Helminth Infection-Induced Immunotolerance and Consequences for Human Papillomavirus Persistence.
Clark EH; Gilman RH; Chiao EY; Gravitt PE
Am J Trop Med Hyg; 2021 Jul; 105(3):573-583. PubMed ID: 34280146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
